The efficacy of anti-RAS therapies, such as AT1R blockers (ARBs) and Ang converting enzyme inhibitors (ACEIs), in slowing progression of renal dysfunction, treating hypertension, and reducing cardiovascular complications confirms the important role of the AT1R signaling pathway in these disorders [3, 10, 11]. This evidence concerns the gene AGTR1 and hypertensive disorder.